Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease (VostatAD01)

Multicenter, Open-label Phase Ib Dose-escalation and Dose-confirmational Study for the Tolerability and Safety of N-hydroxy-N'-Phenyl-octanediamide (Vorinostat) in Patients With Mild Alzheimer's Disease

This Clinical Trial is an open, non-randomized Phase Ib study to determine the maximal tolerable dose (MTD) of Vorinostat in Alzheimer disease (AD) patients between (including) 55 and 90 years with mild symptoms. The MTD in this study is defined as the dose that leads to maximum toxicity with Common Toxicity Criteria (CTC) grade 1 symptoms.The safety and tolerability of Vorinostat in this group of study participants should be tested.

The MTD of Vorinostat in the treatment of Alzheimer's patients is to be determined by using an open, non-randomized, multicentric dose-finding study with adaptive design. This Clinical Trial will take place in 2 parts. The first part will be performed as a dose escalation part in cohorts of three subjects. Possible dosages will be: one, two, three or four capsules (100 mg per capsule) once per day. The first cohort receives a dose of 100 mg per day. After the treatment, a Vorinostat-free follow-up phase will take place. For the following cohorts, dose increases, a repetition of the previous dose or a dose reduction are possible. After the dose escalation with a determination of the MTD, a dosage confirmation is carried out with additional subjects. The subjects are given a dose of Vorinostat of MTD over 4 weeks followed by a Vorinostat-free follow-up phase.

N-hydroxy-N'-phenyl-octanediamide (Vorinostat) capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects

N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects

A MTD is defined as the highest dose with no > grade 1 toxicity according to Common Toxicity Criteria (CTC). The dose-limiting toxicity (DLT) is defined as the dose, which leads with a 30% chance of toxicity to CTC Grade 2 or higher and / or leads to corrected QT interval (QTc)≥480ms and/or increase of QTc >= 50ms compared to baseline

The analysis of safety assessments will include the following data collected for each subject: - Adverse Events (AEs) in the context of Drug Exposure (days)

Blood and plasma area under the concentration time curve of Vorinostat from time zero to 8 hours postdose. The pharmacokinetic study will investigate the correlation between dose administered and concentration of Vorinostat in blood.

association of alterations in the genome-wide transcriptome profile with the dose administered, toxicity and treatment response - pharmacodynamics

The genome-wide transcriptome profile will be determined as a pharmacodynamic surrogate parameter. Alterations between baseline and after dose administered will be compared. The pharmacodynamic study will investigate the correlation between dose administered, alterations in the genome-wide transcriptome profile as well as treatment responses (memory performance) and toxicities.

Inclusion Criteria: written informed consent to participate in the study verified capacity to consent by a doctor not involved in the study mild Alzheimer's disease (NINCDS / ADRDA criteria and Mini-Mental State Examination (MMSE) 22-27) age (including) from 55 to 90 years subjects must be able to meet the requirements described in the study protocol outpatient living Informant lives with subject in the same household Rosen modified Hachinski ischemia score ≤4 concerning only female patients: postmenopausal concerning only male patients: commitment to use a suitable contraceptive cerebral imaging study (CT or cMRI), which is consistent with a diagnosis of probable Alzheimer's disease (not older than 3 years) Exclusion Criteria: other neurological and psychiatric diseases explaining cognitive deficits better than an AD diagnosis conspicuous MRI / CCT scan explaining the cognitive deficits better than an AD diagnosis severe physical, neurological or psychiatric disorders that interfere with the participation in the study history of malignant tumors except non- metastasizing basal cell carcinoma of the skin history of seizures dysphagia leading to the inability to swallow capsules untreated severe acute infections with clinical symptoms such as respiratory infections, pneumonia, bronchitis, acute diarrhea, influenza, untreated urinary tract infections in the family history, unexplained sudden cases of heart failure before the age of 50 years long QT syndrome in the family history evidence of QTc prolongation ≥480 ms at screening (Fridericia adjusted QT interval), of arrhythmias especially of severe uncontrolled ventricular arrhythmias or atrial fibrillation in ECG not sufficiently treated angina heart failure (NYHA III, IV) myocardial infarction known infection with HBV, HCV and / or HIV occurrence of venous thrombosis or embolism therapy with antidepressants begun in the last 12 weeks or dose modification of a pre-existing therapy with antidepressants antidiabetic treatment begun in the last 12 weeks or dose modification of pre-existing antidiabetic treatment long-term use of anti-inflammatory drugs except acetylsalicylic acid for cardiovascular prophylaxis current treatment or treatment within the past 12 weeks with HDAC inhibitors (eg valproate) taking medication that may increase the dose-dependent side effects myelosuppression or QTc interval prolongation. These include, but are not limited to: Class Ia antiarrhythmic agents such as quinidine, procainamide, disopyramide Class III antiarrhythmic drugs such as amiodarone, sotalol, ibutilide Class Ic antiarrhythmics such as flecainide, propafenone penicillamine opioids such as methadone and pyrazolone derivatives such as metamizole and Propyphenazone doxorubicin, epirubicin macrolides and their analogues such as erythromycin, clarithromycin telithromycin oxazolidinones such as linezolid quinolones such as moxifloxacin, levofloxacin fluoxetine, maprotiline tricyclic and tetracyclic antidepressants chlorpromazine, pimozide, haloperidol, droperidol, ziprasidone and clozapine antiemetics azole like ketoconazole, fluconazole, voriconazole aminocholine such as primaquine pentamidine such as quinine, chloroquine diaminopyrimidine such as pyrimethamine salbutamol and formoterol methotrexate azathioprine, cyclosporine Interferon gamma 1b alemtuzumab, basiliximab, efalizumab, natalizumab sunitinib, nilotinib, lapatinib mitoxantrone, Hydroxycarbamide, mercaptopurine taking of prescription and non-prescription drugs for cognitive enhancement (except cholinesterase inhibitors and memantine at a stable dose for at least 3 months before baseline) therapy with anticoagulants except acetylsalicylic acid HbA1c in screening more than 10% above the upper limit of normal magnesium, sodium, calcium and potassium levels outside the normal range (at screening and baseline) existing anemia with Hb <11 (at screening and baseline) existing thrombocytopenia; platelet ≤150.000 / ul, leukocytes ≤ 3.000 / ul, neutrophils absolutely ≤ 1.500 / ul (at screening and baseline) prothrombin or INR ≥ 1.5 above the laboratory limit of normal; PTT ≥ 1.5 x above the laboratory limit of normal (at screening and baseline) clinically relevant renal and / or hepatic impairment at screening and baseline (total bilirubin ≥ 1.5 x above the upper limit of the norm and / or GPT, AST ≥ 4x above the upper limit of the norm and / or creatinine ≥ 1.5x above the upper limit of the norm and / or creatinine clearance <60 ml / min) hematuria> 15 RBCs / mL at screening and baseline proteinuria at screening and baseline except in asymptomatic urinary tract infections participating in other clinical and therapeutic trials within the last 12 weeks relevant only for dose confirmation: subjects with existing contraindications for performing an MRI if no MRI available from the period of 6 months prior to screening cardiac pacemaker metal objects in the body, which exclude a 1.5 or 3 T MRI claustrophobia

Garcia AA, Koperniku A, Ferreira JCB, Mochly-Rosen D. Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives. Trends Pharmacol Sci. 2021 Oct;42(10):829-844. doi: 10.1016/j.tips.2021.07.002. Epub 2021 Aug 10.